fluoxetine has been researched along with simvastatin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Kanitra, L; Moore, R; Mulligan, TE; Zhi, J | 1 |
| Archer, SL; Michelakis, ED | 1 |
| DeLorenzo, ME; Fleming, J | 1 |
| Di Benedetto, B; Ganal, V; Holsboer, F; Kessler, JS; Kirmeier, T; Nothdurfter, C; Rammes, G; Rein, T; Rupprecht, R; Tanasic, S; Wagner, EM | 1 |
| Corbett, AM; Flannery, T; Lizzi, J; Sanghvi, S; Sibbit, B; Sieber, S; Wyatt, N | 1 |
| Akhondzadeh, S; Farokhnia, M; Gougol, A; Iranpour, N; Raheb, S; Salimi, S; Yekehtaz, H; Zareh-Mohammadi, N | 1 |
| Berk, M; Brownstein, DJ; Dodd, S; Fernandes, BS; Salagre, E | 1 |
| Davoudi, S; Dolatshahi, M; Ghorbanzadeh, B; Naserzadeh, R; Paridar, Y | 1 |
| Abushamma, A; Corbett, AM; Gagle, S; Johnson, A; Nagarajan, D; Sharma, N; Sulehria, T | 1 |
| Abdel-Rafei, MK; Moustafa, EM; Rashed, ER; Thabet, NM | 1 |
3 review(s) available for fluoxetine and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antidepressive Agents; Atorvastatin; Citalopram; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
2 trial(s) available for fluoxetine and simvastatin
| Article | Year |
|---|---|
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hypolipidemic Agents; Lactones; Lipase; Male; Middle Aged; Orlistat; Simvastatin | 2003 |
Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Severity of Illness Index; Simvastatin; Treatment Outcome; Young Adult | 2015 |
19 other study(ies) available for fluoxetine and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Individual and mixture effects of selected pharmaceuticals and personal care products on the marine phytoplankton species Dunaliella tertiolecta.
Topics: Carbamazepine; Chlorophyta; Clofibric Acid; Diclofenac; Drug Interactions; Fluoxetine; Household Products; Phytoplankton; Simvastatin; Triclosan; Water Pollutants, Chemical | 2008 |
Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants.
Topics: Animals; Anticholesteremic Agents; Antidepressive Agents; beta-Cyclodextrins; Biophysics; Cholesterol; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Fluoxetine; Humans; Imidazoles; Membrane Microdomains; Membrane Potentials; Mice; Neuroblastoma; Patch-Clamp Techniques; Receptors, Serotonin, 5-HT3; Serotonin; Simvastatin; Sulfhydryl Compounds; Time Factors; Transfection | 2010 |
Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke.
Topics: Animals; Ascorbic Acid; Brain; Brain Ischemia; Drug Therapy, Combination; Female; Fluoxetine; Male; Neurogenesis; Rats; Rats, Long-Evans; Rats, Wistar; Recovery of Function; Simvastatin; Stroke | 2015 |
Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Tolerance; Fluoxetine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Locomotion; Mice; Morphine; Naloxone; Narcotic Antagonists; Open Field Test; Receptors, Opioid; Simvastatin; Substance Withdrawal Syndrome; Swimming | 2020 |
Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis?
Topics: Animals; Ascorbic Acid; Cell Proliferation; Drug Therapy, Combination; Female; Fluoxetine; Lateral Ventricles; Male; Multiple Sclerosis, Chronic Progressive; Neural Stem Cells; Neurogenesis; Rats, Sprague-Dawley; Sex Factors; Simvastatin | 2020 |
Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Biopterins; Brain; Brain Injuries; Cranial Irradiation; Depression; Fluoxetine; Gamma Rays; Inflammation; Male; Neuroprotective Agents; Nitric Oxide; Oxidative Stress; Rats; Signal Transduction; Sildenafil Citrate; Simvastatin | 2021 |